A Phase 4 interventional study of Clopidogrel and Atorvastatin in Carotid Stenosis, sponsored by Campus Bio-Medico University. Status unknown at 1 site in Italy. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2012-04-06.
Sponsored by Campus Bio-Medico University · Phase 4, Interventional, and Prevention
The purpose of this study is to evaluate the efficacy and safety of two different loading doses of Clopidogrel and a reloading of Atorvastatin in the prevention of periprocedural ischemic brain damage in patients undergoing carotid angioplasty.
339 studies on the registry are indexed under Carotid Stenosis; 81 are open to participants now.
This study's planned enrollment of 150 is above the median of 106 across 182 interventional studies indexed under Carotid Stenosis.
Browse Carotid Stenosis studies →Campus Bio-Medico University is the lead sponsor of 82 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Clopidogrel 600 mg after carotid artery stenting
Drug: Clopidogrel
Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
Drug: Atorvastatin
Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
Cerebral damage
Incidence of stroke at 30 days (defined as a neurologic deficit lasting\> 24 hours with MRI evidence of cerebral ischemic injury) or transient ischemic attack (TIA); - Evidence of new onset acute ischemic lesions on MRI-DWI brain after the procedure, even in the absence of specific neurological symptoms
Time frame: 30 days
Bleeding complications
Effect on the 30-day major and minor bleeding (according to the TIMI definition); - Incidence of post-procedural vascular complications (pseudoaneurysm, AV fistula, hematoma\> 5 cm).
Time frame: 30 days
This study is status unknown, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Campus Bio-Medico University